NCT05774951 2026-04-13
CAMBRIA-1
AstraZeneca
Phase 3 Recruiting
Clinical Trials
30 trialsNCT06440967 2026-04-06
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT05514054 2026-04-02
EMBER-4
Eli Lilly and Company
Phase 3 Active not recruiting
NCT06492616 2026-03-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3 Recruiting
NCT07349069 2026-03-19
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Recruiting
NCT05306340 2026-01-30
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Genentech, Inc.
Phase 3 Active not recruiting
NCT04906395 2026-01-13
OVELIA
Tolmar Inc.
Phase 3 Active not recruiting
NCT05645536 2026-01-12
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
Phase 3 Enrolling by invitation
NCT06449027 2025-10-01
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT05128773 2025-09-16
AMEERA-6
Sanofi
Phase 3 Terminated
NCT05952557 2025-06-19
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT02278120 2024-03-12
MONALEESA-7
Novartis
Phase 3 Completed
NCT05780567 2023-04-21
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT00171704 2017-03-03
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Novartis
Phase 3 Completed
NCT00036270 2015-10-28
TEAM
Pfizer
Phase 3 Completed
NCT00038467 2014-05-07
IES
Pfizer
Phase 3 Completed
NCT00291759 2013-01-30
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
AstraZeneca
Phase 3 Completed
NCT00605267 2012-09-06
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
AstraZeneca
Phase 3 Completed
NCT00241449 2012-06-06
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
AstraZeneca
Phase 3 Completed
NCT00849030 2012-06-06
ATAC - Arimidex, Tamoxifen Alone or in Combination
AstraZeneca
Phase 3 Completed
NCT00279448 2011-12-23
TEAM
Pfizer
Phase 3 Completed
NCT00152178 2011-07-07
The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT00233610 2011-01-27
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
AstraZeneca
Phase 3 Completed
NCT00232661 2010-02-03
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
AstraZeneca
Phase 3 Completed
NCT00784862 2009-05-15
ATAC - Pharmacokinetics (PK) Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00286117 2009-05-01
ITA - Clinical Study Comparing ARIMIDEXâ„¢ With NOLVADEXâ„¢ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
AstraZeneca
Phase 3 Completed
NCT00784680 2009-05-01
ATAC - Quality of Life Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00814125 2009-05-01
ATAC - Endometrial Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00784940 2009-04-27
ATAC - Bone Density Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00034125 2006-07-19
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
Eli Lilly and Company
Phase 3 Completed